EQL Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	12.54	43.12	22.71	30.92	31.55
Depreciation & Amortization	-	10.1	7.66	7.43	2.76
Other Amortization	-	2.42	0.62	1.14	0.78
Asset Writedown & Restructuring Costs	-	-	0.47	7.84	6.73
Other Operating Activities	28.76	11.23	0.07	8.13	7.2
Change in Accounts Receivable	22.24	-67.15	-14.25	-16.86	-11.69
Change in Inventory	-21.5	-73.41	-40.26	-23.69	0.68
Change in Other Net Operating Assets	-13.68	49.04	11.54	12.72	3.83
Operating Cash Flow	28.36	-24.65	-11.44	27.62	41.83
Operating Cash Flow Growth	-	-	-	-33.98%	-30.34%
Capital Expenditures	-5.44	-6.13	-0.93	-0.46	-0.63
Sale (Purchase) of Intangibles	-61.8	-239.72	-65.34	-20.05	-21.46
Other Investing Activities	-	-0	-	-0	-
Investing Cash Flow	-67.24	-245.84	-66.26	-20.51	-22.09
Long-Term Debt Issued	9.76	357.94	53.97	-	0.6
Long-Term Debt Repaid	-	-25.71	-0.49	-4.07	-6.58
Net Debt Issued (Repaid)	9.76	332.23	53.48	-4.07	-5.98
Issuance of Common Stock	33.48	0.19	0.27	0.19	0.86
Other Financing Activities	-	-	-	0	-
Financing Cash Flow	43.24	332.43	53.74	-3.88	-5.12
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-
Net Cash Flow	4.36	61.93	-23.96	3.23	14.62
Free Cash Flow	22.92	-30.78	-12.36	27.16	41.2
Free Cash Flow Growth	-	-	-	-34.08%	-30.92%
Free Cash Flow Margin	5.30%	-8.24%	-4.68%	10.45%	10.05%
Free Cash Flow Per Share	0.76	-1.03	-0.41	0.92	1.42
Cash Interest Paid	-	13.02	4.01	2.29	2.78
Levered Free Cash Flow	-54.87	-291.16	-89.53	-9.9	1.84
Unlevered Free Cash Flow	-35.81	-283.45	-85.95	-8.42	3.64
Change in Working Capital	-12.94	-91.52	-42.96	-27.83	-7.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.